NASDAQ:ELDN
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. reported net income of −$45.6M in fiscal 2025. The diluted share count rose 68.6%.Summary generated from Eledon Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Mar 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−63.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+68.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −37 | −88 | −43 | n/a | n/a |
| Net income | −35 | −88 | −117 | −36 | −46 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 4Insider transaction report
Aug 4, 2026 - 4Insider transaction report
Aug 4, 2026 - 8-KAmendment to articles or bylaws
Jun 22, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026 - 8-KResults of operations and financial condition
May 13, 2026 - DEF 14AProxy statement
Apr 30, 2026